United Therapeutics Corporation
UTHR
$300.60
-$1.81-0.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.08B | 2.99B | 2.88B | 2.76B | 2.62B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.08B | 2.99B | 2.88B | 2.76B | 2.62B |
| Cost of Revenue | 339.10M | 329.30M | 309.70M | 304.80M | 291.80M |
| Gross Profit | 2.74B | 2.66B | 2.57B | 2.45B | 2.32B |
| SG&A Expenses | 701.00M | 666.10M | 640.40M | 607.20M | 580.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.56B | 1.52B | 1.43B | 1.41B | 1.35B |
| Operating Income | 1.52B | 1.47B | 1.45B | 1.35B | 1.26B |
| Income Before Tax | 1.62B | 1.56B | 1.54B | 1.44B | 1.40B |
| Income Tax Expenses | 374.90M | 353.20M | 343.90M | 327.00M | 331.70M |
| Earnings from Continuing Operations | 1.24K | 1.21K | 1.20K | 1.11K | 1.07K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.24B | 1.21B | 1.20B | 1.11B | 1.07B |
| EBIT | 1.52B | 1.47B | 1.45B | 1.35B | 1.26B |
| EBITDA | 1.60B | 1.55B | 1.52B | 1.41B | 1.33B |
| EPS Basic | 27.71 | 27.11 | 26.46 | 24.34 | 23.11 |
| Normalized Basic EPS | 23.63 | 22.91 | 22.17 | 20.12 | 18.54 |
| EPS Diluted | 25.61 | 25.05 | 24.59 | 22.76 | 21.75 |
| Normalized Diluted EPS | 21.84 | 21.17 | 20.60 | 18.81 | 17.46 |
| Average Basic Shares Outstanding | 179.30M | 178.60M | 180.70M | 183.00M | 185.30M |
| Average Diluted Shares Outstanding | 194.00M | 193.20M | 194.30M | 195.40M | 196.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |